Last reviewed · How we verify
NCT05173168
A Pilot Study to Assess the Safety Profile of resB®
NA trial testing Probiotic Dietary Supplement in Healthy in 22 participants. Completed in 20 January 2022.
20 January 2022
Quick facts
| Lead sponsor | ResBiotic Nutrition, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 23 November 2021 |
| Primary completion | 20 January 2022 |
| Estimated completion | 20 January 2022 |
| Sites | 1 location across Ireland |
Drugs / interventions tested
- Probiotic Dietary Supplement — full drug profile →
Conditions studied
Sponsor
ResBiotic Nutrition, Inc.
Who can join
Adults 18 to 65, any sex, with Healthy or Asthma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study investigates the safety and tolerability of 4-week, twice daily supplementation of resB® Lung Support in asthma patients and healthy participants.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical trial of a probiotic and herbal supplement for lung health.
Wenger NM, Qiao L, Nicola T, Nizami Z, et al · · 2023 · cited 6× · PMID 37384109 · DOI 10.3389/fnut.2023.1168582
Verify or expand the search:
- PubMed search for NCT05173168
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Probiotic Dietary Supplement
Trials testing the same drug.
- NCT04044144 — Prospective Tolerability Assessment of a Probiotic Dietary Supplement · NA · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other ResBiotic Nutrition, Inc. trials
Trials by the same sponsor.
- NCT05523180 — A Study to Evaluate the Effect of Probiotic Supplement on Quality of Life · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05173168 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ResBiotic Nutrition, Inc.
- Last refreshed: 29 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05173168.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing